Synergistic Integration of 3D Lung-Like Epithelium with Emerging Technologies

The invention integrates 3-dimensional lung-like epithelium with emerging technologies such as AI, IoT, blockchain, and new materials to create a powerful system for personalized lung tissue engineering, disease modeling, and drug development.

The original patent disclosed methods for growing 3-dimensional lung-like epithelium in vitro. However, the patent's limitations lie in the lack of integration with emerging technologies, hindering its potential for personalized medicine and disease modeling. The new inventive concept addresses this limitation by synergistically combining the patented method with AI, IoT, blockchain, and new materials to create a more powerful system.

The new inventive concept comprises a microfluidic chamber, a pluripotent stem cell source, and an AI-controlled culturing protocol that modulates Wnt and FGF signaling pathways to induce SOX9 and SOX2 protein activity. The system can be integrated with IoT sensors and AI-driven analytics to simulate in vivo lung function and predict drug efficacy. Additionally, the invention includes a blockchain-based decentralized platform for sharing and tracking 3-dimensional lung-like epithelium-derived data, ensuring secure and transparent collaboration among researchers. Furthermore, a composite biomaterial for lung tissue engineering is disclosed, comprising a 3-dimensional scaffold infused with nanoparticles that release growth factors and modulate Wnt and FGF signaling pathways.

The new claims introduce a synergistic integration of 3-dimensional lung-like epithelium with emerging technologies, which is not obvious from the original patent. The inventive step lies in the combination of AI-controlled culturing protocols, IoT sensors, blockchain-based data sharing, and composite biomaterials, which enables a more powerful system for personalized lung tissue engineering and disease modeling.

Alternative embodiments of the inventive concept include using different types of stem cells, such as adult stem cells or cord blood stem cells, and integrating the system with other emerging technologies, such as CRISPR gene editing or synthetic biology. Variations of the composite biomaterial could include using different types of nanoparticles or growth factors.

The inventive concept has significant commercial potential in the fields of personalized medicine, disease modeling, and drug development. The target market includes pharmaceutical companies, biotech companies, and research institutions focused on lung disease research and treatment.